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Abstract  
The genetic basis is unknown for ~60% of normosmic hypogonadotropic hypogonadism (nHH)/Kallmann 
syndrome (KS). DNAs from (17 male and 31 female) nHH/KS patients were analyzed by targeted next 
generation sequencing (NGS) of 261 genes involved in hypothalamic, pituitary, and/or olfactory pathways, or 
suggested by chromosome rearrangements. Selected variants were subjected to Sanger DNA sequencing, the 
gold standard. The frequency of Sanger-confirmed variants was determined using the ExAC database. Variants 
were classified as likely pathogenic (frameshift, nonsense, and splice site) or predicted pathogenic 
(nonsynonymous missense). Two novel FGFR1 mutations were identified, as were 19 new candidate genes 
including: AMN1, CCKBR, CRY1, CXCR4, FGF13, GAP43, GLI3, JAG1, NOS1, MASTL, NOTCH1, NRP2, 
PALM2, PDE3A, PLEKHA5, RD3, TMTC1, and TRAPPC9, and TSPAN11.  Digenic and trigenic variants were 
found in 8/48 (16.7%) and 1/48 (2.1%) patients, respectively. NGS with confirmation by Sanger sequencing 
resulted in the identification of new causative FGFR1 gene mutations and suggested 19 new candidate genes in 
nHH/KS.  
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1. Introduction 
The development of reproductive function in humans is regulated by complex signaling interactions of the 
hypothalamic-pituitary-gonadal (HPG) axis. Disruption of any component of this system may result in delayed 
puberty and infertility (Layman, 2013).  Central nervous system defects may impair GnRH action and function 
resulting in GnRH deficiency, also known as hypogonadotropic hypogonadism, which may be manifested 
clinically by low sex steroids and low or inappropriately normal gonadotropins.  To date, two principle 
conditions constitute deficiency in GnRH signaling, namely normosmic hypogonadotropic hypogonadism 
(nHH) and Kallmann Syndrome (KS).  Patients with KS present with hypogonadotropic hypogonadism and a 
lack of smell due to the impaired migration of GnRH and olfactory neurons.   Apart from pubertal and 
reproductive disturbances, other associated anomalies such as renal agenesis, midfacial defects, neurologic 
defects, and cardiac anomalies have been reported (Layman, 2013,Bhagavath et al., 2006).   
Even with improved knowledge of GnRH development and function, only 40% of all nHH/KS cases can be 
explained by reported mutations in more than 30 genes. Some mutations occur in ligand/receptors such as 
KAL1/FGF8/FGFR1/HS6ST1, LEP/LEPR, GNRH1/GNRHR, PROK2/PROKR2, KISS1/KISS1R, and 
TAC3/TACR3.(Layman, 2013) Other identified genes include NR0B1, CHD7, NELF, WDR11, SEMA3A, 
SOX10, FGF17, IL17RD, DUSP6, SPRY4, FLRT3, FEZF1, STUB1, HESX1, PCSK1, RNF216, and OTUD4 
(Layman, 2013,Hanchate et al., 2012,Tornberg et al., 2011,Margolin et al., 2013). These causative genes were 
identified through linkage analysis, candidate gene approaches, and positional cloning (Layman, 2013,Kim et 
al., 2010,Kim et al., 2008). The inheritance pattern of nHH/KS includes X-linked recessive, autosomal 
dominant, autosomal recessive, sporadic, and at least several percent appear to be digenic/oligogenic (Quaynor 
et al., 2011,Sykiotis et al., 2010).  Molecular studies performed by both in vitro and in vivo analysis of the genes 
indicate that either the development/migration or signaling of GnRH is altered or impaired (Layman et al., 
1998,Quaynor et al., 2013).   
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The majority of molecular causes of nHH/KS are yet to be characterized. This gap in our understanding may 
be narrowed with advancements in massively parallel deep resequencing methods, otherwise known as next 
generation sequencing (NGS), which includes targeted NGS, whole exome sequencing, and whole genome 
sequencing.  More expedient, less expensive, and theoretically more accurate results should be able to be 
obtained using NGS (Metzker, 2010).  The goal of the present study was to identify new nHH/KS candidate 
genes using targeted NGS of potentially relevant known genes that are involved in GnRH and olfactory neuron 
development, migration and signaling.  
 
2. Materials and Methods 
 
2.1 Genes Selected for NGS   
The list of 261 genes was gathered from the literature to identify important genes involved in hypothalamic 
or pituitary development, GnRH or olfactory neuron specification, migration, or regulation, nHH/KS known 
pathway genes, or genes located near derivative chromosome breakpoints in nHH/KS patients with 
chromosome translocations (genes shown in Table 1; references for gene selection shown in Supplemental 
Table 1). All known nHH/KS genes at the time of the study initiation in 2011 were also included.(Layman, 
2013) For most genes, 95-100% of the desired sequence was covered—protein coding exons and splice 
junctions, but it was not 100% of all candidate genes. For 7 genes, FAM60A, FGF20, FGF7, GSTM1, HS6ST1, 
TUBB2A, and TUBB2B, the coverage ranged from 61-89.2% (Supplemental Table 2). 
 
2.2 Patients 
Hypogonadotropic hypogonadism was defined as the absence of puberty (age 17 in females; 18 in males) 
with low/normal FSH and LH levels (Bhagavath et al., 2006).  Affected males had serum testosterone levels 
less than 100ng/dL (normal: 300-1100ng/dL), whereas females had absent breast development and 
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hypoestrogenic amenorrhea (Bhagavath et al., 2006).  MRI of the brain and pituitary was normal. Serum 
prolactin, thyroid stimulating hormone (TSH), thyroxine (T4), and cortisol were normal (Bhagavath et al., 
2006).  Patients characterized as nHH exhibited a normal sense of smell by the Smell Identification Test or by 
history, while those with KS had absent or decreased sense of smell (Quaynor et al., 2011).  
Seventeen males (10 with KS, 5 with nHH, and 2 with unknown sense of smell) and 31 females (12 with 
KS, 17 with nHH, and 2 with unknown sense of smell) were studied by NGS. No patients had mutations in any 
known nHH/KS genes; and none had undergone NGS previously. This study was approved by the Augusta 
University Human Assurance Committee, and all patients consented to participate in the study.  
 
2.3 Targeted Next Generation Sequencing 
Genomic DNAs from 48 patients were extracted from blood using phenol-chloroform and ethanol 
precipitation (Xu et al., 2011) and treated with RNAse to remove residual RNA. DNA (2-3ug) was submitted to 
Otogenetics Corporation (Norcross, GA USA) for selected target enrichment and sequencing. Control DNA was 
provided by Otogenetics Corporation.  Genomic DNA was subjected to agarose gel and OD ratio tests to 
confirm the purity and concentration prior to quantification by the Qubit assay (Life Technologies, Grand 
Island, NY USA). DNA fragmentation using restriction enzyme digestion and target enrichment and Illumina 
ready libraries were made using HaloPlex target enrichment kits (Agilent, Santa Clara, CA USA, Catalog# 
G9901B) following the manufacturer’s instructions. Enriched libraries were tested for enrichment, size 
distribution, and concentration by an Agilent 2200 TapeStation. For the selected genes, 261 target IDs were 
resolved to 285 targets comprising 3099 regions of the genome. 
DNA sequencing was performed on an Illumina HiSeq2000 to generate paired-end reads of 100 nucleotides 
and >30X coverage. Burrows-Wheeler Aligner (BWA) was used to map sequence reads to the genome; 
Genome Analysis Toolkit (GATK) was utilized to call exome-wide variants; and SnpEff was used to annotate 
variants (missense, nonsense, etc.). Sequence was filtered to exclude synonymous changes and variants in SNP 
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database v132. Selected variants confirmed by Sanger sequencing were also assessed for frequency in the ExAC 
database (http://exac.broadinstitute.org/).  
Binary alignment map (BAM) files of selected variants were manually evaluated to determine if the variant 
was identified close to the ends of the PCR fragments, which could be more problematic to map since A’s are 
placed at the ends of amplicons during PCR. These were classified in 10 percent increments (0-10%, 11-20%, 
21-30%, etc.) based upon the percentage of reads within 10 bp from the end of fragments out of total reads 
(referred to as end reads) in BAM files. Variants were classified according to guidelines from the American 
College of Medical Genetics and Genomics and Association for Molecular Pathology as class 4—likely 
pathogenic (frameshift, nonsense, and canonical splice site) or class 3 (nonsynonymous missense), which were 
predicted deleterious in silico).(Richards et al., 2015)  
The 319 sequence variants identified by GATK were filtered out with the following criteria: 1) depth < 20, 
2) the number of patients with alternative allele > 5, 3) known variants, and 4) non-coding. The minimum, 
average, and maximum depths (DP) of the final variants are 95, 8425, and 12000, respectively. The minimum, 
average, and maximum quality scores (QUAL) of the final variants are 21, 1970, and 15995, respectively. 
 
2.4 Sanger Sequencing of Variants   
Sanger sequencing is considered the gold standard to confirm or refute nucleotide changes found by NGS. 
Any variant found by NGS is only preliminary—it must be confirmed by Sanger DNA sequencing to consider it 
as a bonafide variant. Only genes in which variants found by NGS and subsequently verified by Sanger 
sequencing were considered as being new candidate genes. Those variants identified by NGS, but not confirmed 
by Sanger sequencing, were considered to be false positives. 
Selected class 4 variants were subjected to Sanger sequencing and available family members were studied 
for the presence or absence of the variant (Quaynor et al., 2011). To prioritize missense variants, three different 
bioinformatic programs were used: SIFT (Sorting Intolerant from Tolerant) (Ng et al., 2003), Mutation Taster 
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(Schwarz et al., 2010), and PolyPhen2 (Polymorphism Phenotyping) (Adzhubei et al., 2010). Missense variants 
were selected for PCR-based Sanger sequencing if >2 programs predicted that the variant would be deleterious. 
The prevalence of the variant was ascertained using the ExAC Database (http://exac.broadinstitute.org/), which 
consists of sequence data from ~61,000 individuals. Sanger sequencing was performed on these variants to 
determine if targeted capture sequencing was correct (Layman et al., 1997). Available family members were 
then studied to assess segregation of the variant with the phenotype. 
 
2.5 The Reproducibility of Targeted NGS 
There was concern regarding the high prevalence of false positive results by targeted NGS. As part of this 
project, we wanted to determine if the location of the variant near the end of the PCR product, as viewed in 
BAM files, affected the reliability of the targeted NGS. Therefore, 90 of our 107 variants (combination of all 
variants) were categorized based upon the percentage of reads within 10bp of the ends of fragments (end reads). 
As can be seen in Supplemental Table 3, when < 70% of the reads were within 10bp of the ends of fragments, 
correct variant calls by Sanger sequencing occurred in 21/63 (33.3%), range of 0-42.9%. However, for 71-100% 
end read calls, only 1/27 (3.7%), range of 0-16.7%, were confirmed by Sanger sequencing.  
Of the class 4 variants called by NGS that were subjected to Sanger sequencing, only 10/17 (58.8%) were 
confirmed. Of the class 3 variants, 28/90 (31.1%) were confirmed by Sanger sequencing. Therefore, only 38 of 
107 (35.5%) variants were confirmed when both class 3 and 4 variants were grouped together. It was only these 
Sanger-confirmed variants that were considered to be true variants that could have a potential role in nHH/KS.  
 
2.6 Colony PCR/Sequencing and RT-PCR 
For frameshift variants, PCR was performed, confirmed by agarose gel electrophoresis, and then cloned 
using the TA Cloning Kit according to manufacturers’ instructions. At least 10 colonies were selected for 
Sanger sequencing as described previously (Layman et al., 1997). For variants predicted to affect splicing, 
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reverse transcription PCR (RT-PCR) was performed as described previously (Kim et al., 2008). RNA was 
extracted from lymphoblasts and subjected to RT-PCR. PCR products were then sequenced to determine if exon 
skipping or insertion was present.  
 
3. Results 
319 variants from 261 genes were identified by targeted NGS in 48 nHH/KS patients.  Of the 319 variants 
identified, 56 were class 4 (frameshift, nonsense, and splice site) and 153 were class 3 (missense) variants. The 
remaining 110 variants were located in the 5’UTR, 3’UTR or >10 bp from splice sites in introns, and were not 
studied further. It should be noted that only true variants in genes identified by NGS that were confirmed by 
Sanger sequencing were considered important for nHH/KS (Table 2). 
 
3.1 Class 4 Variants 
Thirty-four class 4 variants found by targeted NGS were excluded from consideration for Sanger sequencing 
confirmation because the reads were seen almost exclusively within 10 bp of the ends of the PCR fragment on 
BAM files and therefore, not likely to become confirmed by Sanger sequencing. Of the 22 variants remaining, 
they were identified in the following genes: AXL, CCKBR, CHAT, FGF3, FGFR1, GAS6, GPRIN2, IGF1, 
MASTL, NRP2, PTCH2, SDR16C5, SOS1, SP8, TRAPPC9 and CHGA. CHGA was not studied further as it was 
mistakenly included in our initial 261 genes selected, with the intention of studying CGA. These variants in 
candidate genes were subjected to Sanger sequencing, which was necessary to confirm the variant observed by 
NGS (Supplemental Table 4).  The variants included start gain, which produce new ATGs or CTGs thereby 
initiating translation (which was unexpectedly called by SnpEff), frameshift, splice site, and nonsense. Three 
other variants in three genes (GAS6, IGF1 and SDR16C5) were not subjected to Sanger sequencing because 
they were classified as start gain, but did not create a new ATG or CTG (start gain variants produce new ATGs 
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or CTGs which could initiate translation) (Dever, 2012). In total, 10/17 (59%) class 4 variants were positively 
confirmed by Sanger sequencing. 
 
3.2 FGFR1 Mutations 
FGFR1 has been shown to be involved in ~10% of IHH/KS patients (Layman, 2013).   Three previously 
unreported FGFR1 variants, all of which were heterozygous and absent in the ExAC database, were identified 
and confirmed by Sanger sequencing. These variants included one intronic insertion 3bp from the exon 16 
splice donor site region, one nonsense, and one frameshift variant (Table 2).   
In the first patient, an insertion near a splice donor site (c.2180+3insT) of FGFR1 yielded a single wild type 
band from RT-PCR from lymphoblast RNA prior to sequencing, arguing against alternative splicing. Sanger 
sequencing revealed that the unaffected father and unaffected sister were also heterozygotes, suggesting that it 
is a polymorphism (Table 2; pedigree not shown). In the second patient, a c.313C>T (p.Q72X) variant created a 
premature stop codon within the linker region of FGFR1, which was predicted to result in protein truncation. By 
Sanger sequencing, the mother was unaffected, but the father was not available for study (Table 2; Figure 1A). 
This patient also had a heterozygous missense variant in a second gene—GLI3 (see below), which was not 
observed in her mother (Table 3; Figure 1A).  In the third patient, a frameshift mutation in FGFR1 (c.2248delG, 
p.E750Kfs*9K) resulted in 8 altered amino acids following the deletion before a premature stop codon.  DNA 
from the father was not available, but her mother did not have the variant. This patient also had a missense 
variant in AXL that was absent in her mother (Tables 2 & 3; Figure 1B). Sanger sequencing chromatograms are 
only shown for both FGFR1 class 4 mutations in Supplemental Figure 3. 
 
3.3 Other Class 4 Variants 
Complex variants (heterozygous 9bp insertion and missense variants) were observed in GPRIN2 and a start 
gain variant was seen in MASTL and in AXL. However, the GPRIN2 variants were seen in unaffected family 
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members. The MASTL and AXL variants did produce a new ATG and CTG, respectively, which are both 
potential new protein translation start sites (not shown). For both MASTL and AXL variants, available unaffected 
family members did not possess the variant (Table 2).  In total, only two class 4 variants, both in FGFR1, are 
more definitively contributive to the disease phenotype (Table 2). However, it is possible that the start gains in 
MASTL and/or AXL could be pathogenic, but these will require further in vitro translation studies (suggesting 
they are better characterized as class 3 variants).  
 
3.4 Class 3 Variants 
One hundred fifty three missense variants were identified by NGS in our cohort of 48 nHH/KS patients, and 
90 variants were predicted to be deleterious by >2 protein prediction programs.  These 90 variants were 
subjected to Sanger DNA sequencing, but only 30 (33.3%) of the variants were confirmed (Tables 2& 3), all of 
which were heterozygous. The frequency of each confirmed variant in the ExAC database is shown in Table 2 
(only confirmed variants by Sanger sequencing are shown). Heterozygous missense variants were identified in 
five known nHH/KS genes—FGFR1, GNRH1, GNRHR, IL17RD, and AXL, all of which were predicted to be 
deleterious by >2 of 3 programs. Additional missense variants were found in the following genes—AMN1, 
CCKBR, CRY1, CXCR4, FGF13, FGFR3, GADL1, GAP43, GLI3, GPRIN1, JAG1, NOS1, NOTCH1, NRP2, 
PALM2, PDE3A, POMC, RD3, SEMA4D, SMO, TMTC1, TRAPPC9, and TSPAN11 (Table 2A & B). When 
available family members were studied, some of these variants were seen in unaffected family members, 
consistent with probable polymorphisms (Table 2B; ). Therefore, 19 novel candidate genes were identified and 
include: AMN1, CCKBR, CRY1, CXCR4, FGF13, GAP43, GLI3, JAG1, NOS1, MASTL, NOTCH1, NRP2, 
PALM2, PDE3A, PLEKHA5, RD3, TMTC1, and TRAPPC9, and TSPAN11.   (Table 2A). Thirteen genes were 
physiologic candidates, while six genes (AMN1, MASTL, PDE3A, PLEKHA5, TMTC1, and TSPAN11) were 
positional candidates from reported translocations.(Bhagavath et al., 2006,Kim et al., 2008). 
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Initially, nine patients had digenic and two patients had trigenic variants (Table 4). Segregation patterns are 
shown in Figure 1. By chance, half of the pedigrees would be expected not to segregate with the variant if they 
were polymorphisms. Although not all parents were available, nine of eleven pedigrees were consistent with the 
possibility of digenic or trigenic segregation (Figure 1). In most cases, the proband was heterozygous for both 
variants and they were absent in the one parent studied. Alternatively, the proband had two variants, but no one 
unaffected had both (although they could be heterozygous for one variant). Two pedigrees suggested a 
polymorphism because the proband and an unaffected relative were heterozygous for trigenic or digenic 
variants (Figure 2).  
Although not digenic, the CCKBR gene missense variant c.500C>T (p.T167M) was observed in a large 
family, and segregated with both nHH and KS suggesting that it could potentially be detrimental (Table 2; 
Figure 1J). Three family members with KS and one with nHH were heterozygous for this CCKBR missense 
variant. Interestingly, one relative heterozygous for the variant had a brain glioma, and two unaffected 
individuals were wild type. 
 
 
4. Discussion 
 The molecular basis of nHH/KS has been elucidated for 30-40% of all patients. When there is a family 
history of nHH/KS, particularly if there are associated anomalies, targeted sequencing of known genes may be 
warranted.(Layman, 2013). However, should results yield no positive findings, further analysis by targeted NGS 
could be considered.  Despite false positive variants, the Sanger sequencing confirmed variants found by 
targeted NGS revealed meaningful results in both known and previously unsuspected nHH/Ks genes. The 
prevalence of mutations in known genes in our cohort of 48 nHH/KS is not inconsistent with that in the 
literature, as FGFR1 mutations have been reported in 6-10% of patients (Pitteloud et al., 2006,Xu et al., 2007). 
In the current study, two of 48 (~4%) had deleterious (class 4) mutations, both of which were in FGFR1. 
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Neither mutation was found in the ExAC database or reported in the literature. In addition, there was one other 
FGFR1 variant, a missense predicted deleterious, totaling 3/48 (6.3%). Other heterozygous variants in known 
genes GNRH1, GNRHR, IL17RD, and AXL were also found in 7/48 (14.5%) of patients.  The prevalence of 
mutations in most genes involved in nHH/KS is only 1-2%, so it is not surprising that variants in other known 
nHH/KS genes were not identified (Layman, 2013).  
In the current study, targeted NGS with Sanger confirmation also resulted in the identification of variants in 
19 new nHH/KS candidate genes. These variants are predicted to be deleterious; and their available pedigree 
analyses do not indicate polymorphisms. The new candidate genes include: AMN1, CCKBR, CRY1, CXCR4, 
FGF13, GAP43, GLI3, JAG1, NOS1, MASTL, NOTCH1, NRP2, PALM2, PDE3A, PLEKHA5, RD3, TMTC1, 
and TRAPPC9, and TSPAN11.  Because targeted sequencing of known genes was performed, mutations in 
unknown genes (i.e., genes not on the panel) would not be identified using our targeted approach as it could be 
with whole exome sequencing (Yang et al., 2013). All 261 genes were selected because of possible involvement 
in GnRH or olfactory nerve specification, migration, and/or function, hypothalamic or pituitary development, so 
they all have potential relevance to nHH/KS. Variants located close to translocation breakpoints may or may not 
have direct relevance by proposed physiology, but could be involved by a position effect upon other genes  
(Kleinjan et al., 2005).  
Class 4 variants, which consist of nonsense, frameshift, and canonical splice site variants, are generally 
considered as likely pathogenic. Although class 3 (nonsynonymous missense) variants may be predicted by 
protein programs to impair function, they will require future study to determine if they impair protein function 
in vitro. This is similarly true for the start-gain variants. Nevertheless, our identification and confirmation of 
variants in 19 new candidate genes suggests that this small subset of genes could be important in nHH/KS. 
Nearly all variants in these new candidate genes are monoallelic, so it is not known if further study of additional 
patients would yield any biallelic variants. As reported by Sarfati et al,(Sarfati et al., 2010), the phenotype could 
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be more severe as with biallelic variants in PROK2 or PROKR2. However, mutations in more than one could 
also contribute to the phenotype.  
We identified nine possible digenic and trigenic pedigrees (~19%), but this will require further 
characterization of a large number of cohorts, animal studies, and cell-based assays (Schaffer, 2013). Digenic or 
trigenic variants have been identified in several percent of nHH/KS patients, but in most cases it is extremely 
difficult to discern whether both variants are sufficient and/or contributing to the phenotype (Quaynor et al., 
2011,Sykiotis et al., 2010). Variants involved in digenic disease could affect the phenotype by synergistic 
heterozygosity of genes in the same pathway, whereas heterozygosity for either variant alone may have no or 
minimal clinical impact upon phenotype (Quaynor et al., 2011). 
 Confirmed missense variants, such as those found in CXCR4, as well as the other candidates, will be studied 
in our large cohort of nHH/KS patients by sequencing the entire protein coding exons and splice site of each 
candidate gene for mutations (Table 5). CXCR4 protein affects sensory axon extension and is known to be 
important in GnRH neuron migration.(Schwarting et al., 2006) Additionally, it may play a role in directional 
migration, proliferation and survival of primordial germ cells (Gu et al., 2009). CCKBR is a particularly 
promising new candidate gene because of its segregation pattern in our large family with nHH/KS. CCKBR, 
encoding the cholecystokinin B receptor, is a G-protein coupled receptor neuropeptide expressed in the 
paraventricular nucleus of the hypothalamus, which is involved in binding cholecystokinin and gastrin 
(Mohammad et al., 2012).Whether it is associated with glioma formation requires further study. Relevance to 
nHH/KS is also available for the other candidate genes— AMN1 (Bhagavath et al., 2006,Wang et al., 2003), 
CRY1 (Wunderer et al., 2013), FGF13 (Itoh et al., 2004), GAP43 (Strittmatter et al., 1995), GLI3 (Balmer et al., 
2004), JAG1 (Ratie et al., 2013), MASTL (Bhagavath et al., 2006,Johnson et al., 2009), NOS1 (Leshan et al., 
2012,Garrel et al., 2010), NOTCH1 (Ratie et al., 2013), NRP2 (Cariboni et al., 2011), PALM2 (Panza et al., 
2007), PDE3A  (Masciarelli et al., 2004), PLEKHA5 (Dowler et al., 2000), RD3 (Friedman et al., 2006), 
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TMTC1(Sunryd et al., 2014), TRAPPC9 (Lorenc et al., 2014), and TSPAN11(Bassani et al., 2012). All of these 
genes represent reasonable physiologic or positional candidates (Table 5).  
 Six of the candidate genes were selected for the sequencing panel because they were near translocation 
breakpoints: AMN1, MASTL, PDE3A, PLEKHA5, TMTCI, and TSPAN11 (Table 5).(Bhagavath et al., 2006,Kim 
et al., 2008) However, these positional candidates may also have some plausible physiologic roles in nHH/KS.  
TSPAN11 regulates cell adhesion, motility, and synapse formation;(Bassani et al., 2012) PLEKHA5 is expressed 
in the brain and interacts with phosphatidylinositol trisphosphate, an important second messenger in G-protein 
coupled receptors;(Dowler et al., 2000) and TMTC1 is involved in calcium homeostasis.(Sunryd et al., 2014)  
The other positional candidates are involved in cell cycle exiting (AMN1),(Wang et al., 2003) cell division 
(MASTL),(Johnson et al., 2009) and meiosis resumption (PDE3A).(Masciarelli et al., 2004)  
Of the remaining 13 new candidate genes, two would be predicted to be involved in nHH/KS—FGF13 is 
related to other FGF/FGFR genes FGFR1 and FGF8, which are genes known to have mutations in nHH/KS 
patients.(Itoh et al., 2004) Similarly, known KS gene SEMA3A encoding semaphorin 3A, binds to one of its 
receptors—neuropilin 2, encoded by NRP2 (Table 5).(Cariboni et al., 2011) PALM2 is expressed in the 
olfactory bulb and was proposed to be a KS gene as one patient had a translocation disrupting this gene.(Panza 
et al., 2007). Two candidates are ligand and receptor--JAG1 encoding Jagged 1, which binds to its receptor, 
NOTCH, encoded by NOTCH1, which are involved in cell differentiation and morphogenesis.(Ratie et al., 
2013). GLI3 is a very viable candidate gene because it is involved in the sonic hedgehog pathway, which 
regulates multiple body processes including induction, patterning, and differentiation. It affects olfactory exons 
and their directed outgrowth to the telencephalon.(Balmer et al., 2004) NOS1 has well known vascular 
functions, but it is also known that GnRH increases NOS1 expression in pituitary gonadotropes. CRY1 is 
pituitary clock gene thought to regulate the feedback loop of CLOCK-BMAL;(Wunderer et al., 2013); GAP43 
regulates growth of axons and moderates the formation of new neuronal connections(Strittmatter et al., 1995); 
RD3 is highly expressed in the retina and is involved in transcription and splicing;(Friedman et al., 2006); and 
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TRAPPC9, within the Prader-Willi region, is highly expressed in the brain and appears to regulate the NF-
kappaB signaling pathway.(Lorenc et al., 2014)  These candidates are summarized in Table 5.  
The goal of targeted capture sequencing is to rapidly and accurately identify disease-causing variants. In this 
study, many variants were identified requiring confirmation by Sanger sequencing; however, a majority were 
false positives.  Possible explanations for this high rate of false positives could have to do with the procedure in 
which the DNA was sheared by restriction enzyme digestion rather than a random method (such as sonication), 
depth of reads, quality assessment, read alignment, variant identification, and/or annotation (Pabinger et al., 
2014). The degree to which variants were missed—the false negatives—is not able to be addressed in this study. 
However, the confirmed variants do provide exciting new possibilities that require future study.    
In conclusion, we have identified two new likely pathogenic FGFR1 mutations and 19 new candidate 
nHH/KS genes. These additional candidates will require future study in a large cohort of nHH/KS patients to 
determine their role in the phenotype. Although targeted capture sequencing permits the study of a large number 
of genes simultaneously, technical improvements of NGS are necessary before widespread use can be 
considered for routine diagnostic utility. Since the cost of whole exome sequencing is now competitive with 
targeted NGS done in our study, it is likely this method will be utilized for our future studies. Nevertheless, 
those variants confirmed by Sanger sequencing in this study yield important new genes for consideration in the 
pathogenesis of nHH/KS and a role in normal puberty. 
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Figure 1. 
Digenic and trigenic pedigrees are shown (A-I), as well as an informative CCKBR family (J). Each pedigree is 
labeled with a letter A to J, which corresponds to the specific variant of the same letter in Table 4. Only variants 
identified by targeted NGS that were positively confirmed by Sanger sequencing are included in the analysis. 
 
Figure 2 
Two families of possible digenic or trigenic disease are shown, which are not informative. Since the variants do 
not segregate with nHH/KS, it is likely they are polymorphisms. Note for Figure 2A, the genotype of the father 
for SMO was not able to be done due to insufficient DNA. 
 
Table 1. 261 genes selected for targeted sequencing are shown along with the their proposed relevance to 
nHH/KS. Some genes may be listed in more than one column. References for gene selection are shown in 
Supplemental Table 1. 
 
Table 2. (A) Variants identified by targeted NGS in 48 nHH/KS, all of which were confirmed by Sanger 
sequencing, are shown. WT = wild type; HET = heterozygous; KS = Kallmann syndrome; nHH = normosmic 
hypogonadotropic hypogonadism. Findings in available family members are also shown. Note that although 
variants in some genes may not appear to segregate with the phenotype in a monogenic fashion (indicated by an 
asterisk), when evaluated in the context of digenic inheritance, these are still viable potentially pathogenic 
variants (see Figure 1). (B) Shown are the variants that are probable polymorphisms as they do not segregate 
with nHH/KS in a monogenic or digenic fashion. 
 
Table 3. Class 3 missense variants are shown that were confirmed by Sanger sequencing. They were predicted 
deleterious if  >2 or 3 programs (SIFT, PolyPhen2, MutationTaster) indicated so.  
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Table 4. Digenic and trigenic pedigrees are shown. They are labelled A-I and each variant corresponds to the 
same variant indicated by the same letter as in Figure 1. Only variants confirmed by Sanger sequencing (class 3 
or 4) are included. 
 
Table 5. The 19 new candidate genes are shown, and where relevant, human phenotypes in OMIM are 
referenced.  
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IHH Gene 
Accession 
Number 
Variant 
# 
Subjects 
ExAC 
Frequency 
% ExAC 
Frequency 
Subject Phenotype Family History 
 Class 4               
 225 FGFR1 NM_001174063 c.214C>T, p.Q72X 1 0 0 nHH mother WT, unaffected 
 
262 FGFR1 NM_001174063 
c.2248delG, 
p.E750Kfs*9 
1 0 0 nHH mother WT, unaffected 
 Class 3               
 
234 AMN1 NM_001113402 c.656G>A, p.C219Y  1 0 0 nHH 
father HET, unaffected;  
sister1 HET, IHH;  
sister2 HET, unaffected 
 061, 
302 
AXL NM_001699 
c.-40C>T,  
p.L1extM-13  
2 39/17382 0.2244 
subject C: nHH  
subject D: nHH 
subject C: father WT, unaffected; 
subject D: mother WT, unaffected 
 262 AXL NM_001699 c.568C>T, p.R190C   1 1/57944 0.001726 nHH mother WT, unaffected 
 
210 CCKBR NM_176875 c.500C>T, p.T167M  1 3/118692 0.002528 
KS, bilateral hearing 
aids, blind left eye, 
anosmia, benign 
ovarian tumor, no 
breasts 
father (no DNA) undescended testes;  
brother1 HET, IHH hyposmia, undescended 
testes, hearing loss, anger issues, kidney and 
stomach cancer;  
brother2 HET, normosmic, deceased, brain 
glioma;  
sister HET, KS, hearing loss, anosmia, 
bilateral amblyopia,  
sister-in-law WT, unaffected;  
nephew1 HET, hyposmic with undescended 
testes;  
nephew2 WT, unaffected 
 302 CRY1 NM_004075 c.1292G>A,p.R431H  1 29/119292 0.02431 nHH mother WT, unaffected 
 61 CXCR4 NM_003467 c.236A>C, p.H79P  1 0 0 nHH father WT, unaffected 
 
217 FGF13 NM_033642 c.529T>C, p.S177P   1 0 0 KS 
mother WT, unaffected;  
father WT, unaffected;  
brother WT unaffected 
 235 FGFR1  NM_001174063 c.2053G>A, p.G685R 1 0 0 nHH mother WT, unaffected 
 
217 GAP43 NM_002045 c.502G>A , p.A168T  1 0 0 KS 
father HET, unaffected;  
mother WT, unaffected;  
brother HET, unaffected 
 225 GLI3 NM_000168 c.341G>A, p.R114K  1 304/101458 0.2996 nHH mother WT, unaffected 
 
245 GLI3 NM_000168 c.245G>A, p.R82K 1 2/117682 0.00169 nHH 
brother 1 HET nHH  
brother 2  HET unaffected 
 
224 GNRH1 NM_000825 c.103C>T, p.R35C   1 0 0 nHH 
father HET, unaffected;  
mother WT, unaffected;   
sister WT, unaffected 
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245 GNRHR NM_000406 c.662T>A, p.I221N 1 0 0 nHH 
brother 1 HET nHH  
brother 2 WT unaffected 
 233 IL17RD NM_017563  c.965G>A, p.R322H 1 0 0 pituitary tumor mother HET, unaffected 
 
234 JAG1 NM_000214 c.323A>T, p.N108I   1 0 0 nHH 
father WT, unaffected;  
sister WT, unaffected;  
sister HET, nHH 
 
302 MASTL NM_001172303 
c.-170C>T, 
p.M1extM-57 
1 0 0 nHH mother WT, unaffected 
 216 NOS1 NM_001204213 c.1007G>A, p.R336H   1 0 0 nHH sister WT, unaffected 
 119 NOTCH1 NM_017617  c.2333C>T, p.T778I  1 1/118624 0.000843 nHH mother WT, unaffected 
 
310 NRP2 NM_003872 c.2057T>G, p.F686C 1 0 0 nHH, 1˚ amenorrhea 
mother WT, unaffected;  
grandmother WT, unaffected 
 
258 PALM2 NM_001037293 c.451A>G, p.T151A  1 0 0 
KS, 1˚ amenorrhea, 
Graves disease 
none 
 
128 PDE3A NM_001244683 c.1477G>A, p.G493R  1 0 0 nHH 
father HET, unaffected; 
mother WT, unaffected 
sister HET, unaffected 
 
247 PLEKHA5 NM_001143821 c.884A>T, p.N295Y 1 0 0 
Unknown sense of 
smell 
mother HET unaffected 
 216 RD3 NM_001164688 c.509C>T, p.S170F 1 3/105638 0.00284 nHH sister WT, unaffected 
 
307 TMTC1 NM_175861 c.1978G>A, p.D660N 1 0 0 
KS, bilateral 
cryptorchidism, left 
orchiopexy, myopia, 
gynecomastia 
father HET, unaffected 
mother WT, unaffected 
 
128 TRAPPC9 NM_001160372 c.1532C>T, p.T511M 1 0 0 nHH 
father WT, unaffected;  
mother HET, unaffected 
sister WT, unaffected 
 
AO2 TSPAN11 NM_001080509 c.203G>A,  p.G68D 1 0 0 KS, NELF mutation 
father HET, hyposmic, blepharospasm; 
mother WT, unaffected 
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IHH Gene 
Accession 
Number 
Variant 
# 
Subjects 
ExAC 
Frequency 
% ExAC 
Frequency 
Subject 
Phenotype 
Family History 
Class 3                 
165 FGFR1* NM_001174063 c.2180+3insT 1 0 0 nHH 
father HET 
unaffected; 
mother WT, 
unaffected; 
sister HET, nHH 
208 FGFR1* NM_001174063  c.301T>G, p.C101G 1 0 0 KS 
father HET, 
unaffected; 
mother WT, 
unaffected;  
brother HET, anosmic 
6 FGFR3* NM_022965 c.962C>T, p.S321F 1 0 0 
 KS, midline 
high palate 
brother1 HET, 
45,X/46,XY;           
brother2 WT, 46,XY, 
unaffected 
224 GADL1* NM_207359 c.1480C>T, p.R494C 1 2/121188 0.00165 nHH 
father HET, 
unaffected;  
mother WT, 
unaffected;  
sister WT, unaffected 
123 GPRIN1* NM_052899  c.2884C>T, p.R962C  1 0 0 
KS, unilateral 
undescended 
testes 
father WT, unaffected;  
mother HOM, 
unaffected     
165 POMC* NM_000939 c.777C>G, p.I259M  1 0 0 nHH 
father WT, unaffected;  
mother HET, 
unaffected;  
sister HET, nHH  
123 SEMA4D* NM_006378 c.2278C>A, p.L760M   1 0 0 KS 
father WT, unaffected;  
mother HET, 
unaffected  
123 SMO* NM_005631 c.1789G>A, p.D597N    1 0 0 KS 
mother HET, 
unaffected 
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Gene 
Accession 
Number 
Variant SIFT PolyPhen2 MutationTaster 
AXL NM_001699 c.568C>T, p.R190C   Not tolerated; p=0.03 Possibly damaging with a score of 0.909 polymorphism 
CCKBR NM_176875 c.500C>T, p.T167M  Not tolerated; p=0.00 Probably damaging with a score of 1.000 disease causing 
CRY1 NM_004075 c.1292G>A,p.R431H  Not tolerated; p=0.00 Benign with a score of 0.047 disease causing 
CXCR4 NM_003467 c.236A>C, p.H79P  Not tolerated; p=0.00 Probably damaging with a score of 1.000 disease causing 
FGF13 NM_033642 c.529T>C, p.S177P   Not tolerated; p=0.00 Error disease causing 
FGFR1  NM_001174063 c.2053G>A, p.G685R Not tolerated; p=0.00 Error disease causing 
FGFR1* NM_001174063  c.301T>G, p.C101G Not tolerated; p=0.00 Probably damaging with a score of 1.000 disease causing 
FGFR3* NM_022965 c.962C>T, p.S321F Not tolerated; p=0.00 Error disease causing 
GADL1* NM_207359 c.1480C>T, p.R494C Not tolerated; p=0.00 Probably damaging with a score of 1.000 disease causing 
GAP43 NM_002045 c.502G>A , p.A168T  Tolerated; p=0.30 Probably damaging with a score of 1.000 disease causing 
GLI3 NM_000168 c.341G>A, p.R114K  Not tolerated; p=0.02 Probably damaging with a score of 0.995 disease causing 
GLI3 NM_000168 c.245G>A, p.R82K Not tolerated; p=0.00 Probably damaging with a score of 0.994 disease causing 
GNRH1 NM_000825 c.103C>T, p.R35C   Not tolerated; p=0.00 Probably damaging with a score of 1.000 disease causing 
GNRHR NM_000406 c.662T>A, p.I221N Not tolerated; p=0.00 Possibly damaging with a score of 0.912 disease causing 
GPRIN1* NM_052899  c.2884C>T, p.R962C  Not tolerated; p=0.03 Benign with a score of 0.046 disease causing 
IL17RD NM_017563  c.965G>A, p.R322H Not tolerated; p=0.03 Probably damaging with a score of 1.000 disease causing 
JAG1 NM_000214 c.323A>T, p.N108I   Not tolerated; p=0.04 Possibly damaging with a score of 0.645 disease causing 
NOS1 NM_001204213 c.1007G>A, p.R336H   Not tolerated; p=0.03 Error disease causing 
NOTCH1 NM_017617  c.2333C>T, p.T778I  Not tolerated; p=0.04 Probably damaging with a score of 0.963 disease causing 
NRP2 NM_003872 c.2057T>G, p.F686C Not tolerated; p= 0.00 Error disease causing 
PALM2 NM_001037293 c.451A>G, p.T151A  Not tolerated; p=0.00 Possibly damaging with a score of 0.760 disease causing 
PDE3A NM_001244683 c.1477G>A, p.G493R  Not tolerated; p=0.04 Error disease causing 
PLEKHA5 NM_001143821 c.884A>T, p.N295Y Not tolerated; p=0.00 Probably damaging with a score of 1.000 disease causing 
POMC* NM_000939 c.777C>G, p.I259M  Not tolerated; p=0.04 Probably damaging with a score of 0.970 disease causing 
RD3 NM_001164688 c.509C>T, p.S170F Not tolerated; p=0.00 Probably damaging with a score of 1.000 disease causing 
SEMA4D* NM_006378 c.2278C>A, p.L760M   Not tolerated; p=0.00 Probably damaging with a score of 1.000 disease causing 
SMO* NM_005631 c.1789G>A, p.D597N    Not tolerated; p=0.02 Possibly damaging with a score of 0.566 disease causing 
TMTC1 NM_175861 c.1978G>A, p.D660N Not tolerated; p=0.04 Error polymorphism 
TRAPPC9 NM_001160372 c.1532C>T, p.T511M Not tolerated; p=0.00 Probably damaging with a score of 1.000 disease causing 
TSPAN11 NM_001080509 c.203G>A,  p.G68D Not tolerated; p=0.00 Probably damaging with a score of 1.000 disease causing 
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     Gene Name    Locus  Function    Reference 
 
1. AMN1  Antagonist of mitotic   12p11.21 Positional; also   Bhagavath (3) 
exit network 1 homolog   part of daughter-specific 
      switch helping cells exit  Wang (32) 
      and reset cell cycle via 
      G-protein inhibition 
 
2. CCKBR Cholecystokinin B   11p15.4 G-protein coupled receptor           Mohammad (31) 
  receptor      neuropeptide for gastrin and 
cholecystokinin, both of which 
are regulatory peptides of the  
brain and gastrointestinal tract; 
expressed in paraventricular  
nucleus of hypothalamus 
 
3. CRY1 Cytochrome circadian  12q23.3 Pituitary clock gene, binds as  Wunderer (33) 
  clock 1     multiprotein complex in circadian  
        feedback loop of CLOCK-BMAL 
 
4. CXCR4 C-X-C motif chemokine 2q21  Affects sensory axon extension         Schwarting (29) 
receptor 4     and GnRH1 neuron migration; 
maintains GnRH1 neuronal  
expression as the cells move away  
from nasal pit region 
 
5. FGF13 Fibroblast growth   Xq26.3-q27.1 FGFs known in nHH/KS pathway Itoh (34) 
  factor 13     expressed in developing & adult 
        nervous systems (predominantly 
        in brain-cerebellum & cortex) 
 
6. GAP43 Growth associated  3q13.31 Linked to synaptosomal   Strittmatter (35) 
  protein 43     membrane; regulates growth 
        of axons & moderates formation 
        of new connections 
 
7. GLI3 GLI family   7p14.1  Transcriptional regulator of   Balmer (36) 
  zinc finger 3     sonic hedgehog involved 
        in induction, patterning, &  
        differentiation of body regions 
        including face & forebrain; affects 
        olfactory receptor axons & directed 
        outgrowth to telecephalon; 
        haploinsufficiency results in Greig 
        Cephalopolysyndactyly (MIM 175700) 
& Pallister Hall syndrome (MIM 146510); 
(PHS includes hypothalamic 
hamartomas) 
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8. JAG1 Jagged 1   20p12.2 Ligand of Notch receptor, which  Ratie (37) 
is increased by WNT signaling  
molecules (beta-catennin & TCF); 
activates transcription factors  
important in cell differentiation & 
morphogenesis; mutations in Alagille 
syndrome (MIM 118450)-facial,  
cardiac, ocular, & skeletal defects;  
cholestasis 
 
9. MASTL Microtubule-    10p12.1 Positional candidate   Bhagavath (3) 
  associated serine/    Thrombocytopenia (MIM 608221); Johnson (38) 
  threonine kinase    mutations in kinase domain   
  like      in Drosophila disrupt cell division 
 
10. NOS1 Nitric oxide synthase 1 12q24.22 Molecular messenger with diverse Garrel (40) 
        brain & peripheral nervous system 
        functions; GnRH regulates (increases) 
NOS1 in pituitary gonadotropes 
 
11. NOTCH1 Notch, Drosophila  9q34.3  See JAG1 above; mutations in Ratie (37) 
  Homologue of, 1    Adams-Oliver syndrome  
(MIM 616028); aortic 
valve disease 1 (MIM 109730) 
 
12. NRP2 Neuropilin 2   2q33.3  Neuropilins are receptors for   Cariboni (41) 
        semaphorins (SEMA3A is  
known KS gene); expressed on 
vomeronasal nerve, which serves 
as guide for GnRH neuron 
migration  
 
13. PALM2 Paralemmin 2   9q31.3  Disrupted in KS patient with   Panza (42) 
translocation of 9q31.3;also   
        known as A-kinase anchor protein 
        2; expressed in olfactory bulb & 
        cartilaginous structures of embryo 
   
14. PDE3A Phosphodiesterase 3A  12p12  Positional candidate   Bhagavath (3) 
Mutations in brachydactyly & Masciarelli (43) 
        hypertension syndrome  
(MIM 112410); PDE3A is 
responsible for hydrolysis  
of cAMP activity of oocyte 
        (needed for resumption meiosis in egg) 
  
15. PLEKHA5 Plekstrin homology  12p12.3 Positional candidate   Bhagavath (3) 
domain-containing     Expressed at highest levels in  Dowler (44) 
  protein, family A,    ovary, but also in brain; interacts 
  member 5     with phosphatidylinositol 3,4,5- 
      trisphosphate (important 2
nd
  
      messenger in G-protein coupled 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
 
      receptors (nHH/KS genes) 
 
 
16. RD3 Retinal degeneration 3 1q32.3  Highly expressed in retina;  Friedman (45) 
  Mouse, homolog of    part of subnuclear protein  
        complex involved in diverse 
        processes, such as transcription 
        and splicing; Mutations in  
        Leber congenital amaurosis-12 
        (MIM 610612) 
 
17. TMTC1 Transmembrane and   12p11.22 Positional candidate; also  Bhagavath (3) 
tetratricopeptide repeat    endoplasmic reticulum protein Sunryd (46) 
  domains-containing   involved in calcium homeostasis 
  protein 1 
 
18. TRAPPC9 Trafficking protein  8q24.3  Expressed in neurons of the  Lorenc (47) 
  particle complex,     cerebral cortex, hippocampus, 
  subunit 9     and deep gray matter; 
        protein binds NF-kappa-B 
        inducing kinase (NIK) and  
        inhibitor of kappa light chain 
        gene enhancer in B cells, kinase 
        of (IKK-beta); involved in  
        NF-kappa signaling pathway; 
        paternally expressed &  
implicated in Prader-Willi;  
mutations in mental retardation,  
autosomal recessive (MIM 613192) 
  
19. TSPAN11 Tetraspanin 11  12p11.21 Positional candidate; also  Bhagavath (3)  
        integral membrane protein  Bassani (48) 
        regulating cell adhesion, motility, 
        and synapse formation; interacts 
        with integrins 
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Highlights—Quaynor et al. 
 
• Targeted and Sanger DNA sequencing of 261 genes was performed in 48 patients with 
hypogonadotropic hypogonadism 
 
• Two novel FGFR1 likely pathogenic mutations were found 
 
• Nineteen new candidate genes for hypogonadotropic hypogonadism were identified 
 
• Eight possible digenic and one possible trigenic families were identified 
 
 
 
 
